ZZ 1003
Alternative Names: ZZ-1003Latest Information Update: 16 Mar 2022
At a glance
- Originator Zhongze Therapeutics
- Class Antidementias; Antidepressants; Antipsychotics; Vascular disorder therapies
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Major depressive disorder; Schizophrenia; Stroke
Most Recent Events
- 01 Mar 2022 Early research in Alzheimer's disease in China (unspecified route) (Zhongze Therapeutics pipeline, March 2022)
- 01 Mar 2022 Early research in Major depressive disorder in China (unspecified route) (Zhongze Therapeutics pipeline, March 2022)
- 01 Mar 2022 Early research in Schizophrenia in China (unspecified route) (Zhongze Therapeutics pipeline, March 2022)